🇺🇸 FDA
Pipeline program

An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachment inhibitor to an integrase inhibitor-based antiretroviral therapy regimen in adults living with HIV (ENTRANCE)

221794

Phase 1 other active

Quick answer

An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachment inhibitor to an integrase inhibitor-based antiretroviral therapy regimen in adults living with HIV (ENTRANCE) for HIV Infections is a Phase 1 program (other) at ViiV Healthcare BV with 1 ClinicalTrials.gov record(s).

Program details

Company
ViiV Healthcare BV
Indication
HIV Infections
Phase
Phase 1
Modality
other
Status
active

Clinical trials